Newly discovered cellular trigger could lead to possible therapies for Parkinson's disease

Published Date: 26 Jul 2025

Autophagy is essentially the "rubbish collection" of our cells. If there are problems in this process, which is so important for our health, diseases such as Parkinson's can result. In their latest study, leading cell biologists ...

Read Full News

Latest News

HTTP error: 503

2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS Isabella Ciccone, MPH, Sandra Vukusic, MD, PhD

The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
HTTP error: 503

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP Louie Pasculli

A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab Marco Meglio

A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.
HTTP error: 503

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

HTTP error: 503HTTP error: 503

Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.
HTTP error: 503

A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.

New 12-month interim data showed functional gains with BBP-418 vs placebo, consistent benefit across genotype, age, and baseline pulmonary function subgroups, and a safety profile comparable to placebo.

News All Time

HTTP error: 503

NeuroVoices: James Winkley, MD, on Analyzing Phase 3 PREVAIL Trial of Gefurulimab Marco Meglio

The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
HTTP error: 503

This Week on NeurologyLive® — September 28, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.
HTTP error: 503

SHIELD Trial Advances Combination Antiviral for Long COVID Marco Meglio

PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.

Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis Marco Meglio

New PREVAIL trial analyses presented at the 2026 AANEM Annual Meeting showed gefurulimab reduced gMG-related hospitalizations and produced durable symptom and quality-of-life gains through one year.

FDA Approves Tavapadon for the Treatment of Parkinson Disease Isabella Ciccone, MPH

FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
HTTP error: 503

Unexpected Cognitive Improvement Emerges in Hearing Aid Trial

— Treating hearing loss may help some people regain cognitive and functional capacity, data suggest

NeuroVoices: Eva Mistry, MD, on Addressing Secondary Stroke Prevention Gaps in Underserved Populations Eva Mistry, MD , Isabella Ciccone, MPH

The professor of neurology at the University of Cincinnati discussed why disparities persist in secondary stroke prevention and how growing awareness of social determinants of health is helping to close the gap for underserved patients.

Simufilam Clears FDA Hold, Advances to Phase 2 Trial of Tuberous Sclerosis Complex Marco Meglio

The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.

CHMP Recommends EU Approval for Ocrelizumab in Pediatric Relapsing MS Louie Pasculli

The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.
HTTP error: 503HTTP error: 503HTTP error: 503

Recommended News For You

For relapsed or resistant DLBCL, odronextamab produced positive results.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

Trump Issues Gag Order for CDC, FDA; Stalled Hearing for RFK Jr.; Sex After Cancer

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

Lesser-known lobular breast cancer on the rise in U.S. women

Recommended Articles For You

Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology 

The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy 

What Is Degos Disease? A Comprehensive Overview Of Symptoms, Diagnosis, and Treatment 

The Silent Killer: Uncovering the Causes and Treatments of Hemorrhagic Gastritis 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

2.

Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.

3.

Clinical Evidence Shows Venetoclax Combo Is Safe and Effective in AML Patients 80 Years of Age and Up.

4.

The pancreatic ductal adenocarcinoma mRNA vaccine holds promise for preventing relapse.

5.

CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

1.

Engineered Red Blood Cell Therapeutics: Emerging Applications

2.

A New Hope: Exploring Treatment Options for Waldenstrom's Macroglobulinemia

3.

AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined

4.

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors

5.

Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

2.

Chemotherapy: What to Expect

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

4.

From Guidelines to Practice: Hematology

5.

Early Warning Signs of Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot